Notice of Results and Investor Presentation

Paris, France, and Manchester, UK - 8 April 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2025 on Thursday, 30 April 2026.

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2025 results will take place at 11.00am BST on Thursday, 30 April 2026.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

Investors can sign up for the webinar via:

CEO and CFO video

Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer have recorded a video overview relating to the Company's latest acquisition of Southern Cross Diagnostics Pty Ltd and the Preferential Subscription Rights ("PSR") Issue, explaining the strategic rationale behind the acquisition while also expanding on the PSR, why it was undertaken and use of proceeds. Please see link to video: